George R. Painter
Chief Executive Officer at Drug Innovation Ventures At Emory LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michelle LaSpaluto | F | 50 | 13 years | |
| Martha Demski | F | 71 | 19 years | |
| Donald J. Elmer | M | - |
Koronis Pharmaceuticals, Inc.
 Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Michael Alrutz | M | 54 | 12 years | |
| Roy W. Ware | M | - | 17 years | |
| David Jakeman | M | 47 | 15 years | |
| Jeffrey J. Miller | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Graham K. Crooke | M | 65 |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| David A. Krekel | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Richard V. McCloskey | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Dennis Liotta | M | 76 |
Drug Innovation Ventures At Emory LLC
| - |
| Mark G. Fromhold | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Michael G Natchus | M | - |
Emory Institute For Drug Development
 Emory Institute For Drug Development Miscellaneous Commercial ServicesCommercial Services Emory Institute For Drug Development engages in drug discovery and development in industry and academia. It provides organization, facilities and resources to translate academic drug discovery into clinical candidates. The company was founded by Dennis C. Liotta in 2009 and is headquartered in Atlanta, GA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Timothy Wollaeger | M | 80 | 16 years | |
| Kenneth Moch | M | 69 | 5 years | |
| James Niedel | M | 79 | 7 years | |
| Seth A. Rudnick | M | 75 | - | |
| Hervé Momméja-Marin | M | 53 | - | |
| Art Pappas | M | 76 | 3 years | |
| Wende Hutton | F | 63 | - | |
| Timothy Trost | M | 66 | 7 years | |
| Farah Champsi | F | 62 | 4 years | |
| Robert W. Overell | M | 69 | 1 years | |
| Thomas A. Pitler | M | 65 | - | |
| Gwendolyn Powell Painter | M | - | - | |
| Pamela Goss | F | - | - | |
| Karl Y. Hostetler | M | - | - | |
| Edward Penhoet | M | 83 | - | |
| Timothy King | M | - | - | |
| Jung Choi | F | 54 | 2 years | |
| Michelle L. Rose | M | - | 8 years | |
| Randall Lanier | M | - | 16 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 32 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- George R. Painter
- Personal Network
